Zilico designs and manufactures the next generation of medical diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time to clinical screening programmes, globally.

The company has developed its patented Electrical Impedance Spectroscopy (EIS) into a platform technology for cancer diagnosis, including Zilico's flagship product ZedScan™ (cervical cancer diagnostics).

The company will be using the funds to further drive commercial adoption of ZedScan and expand its product development into other clinical areas.



  • Disruptive technology that increases scanning accuracy for cervical cancer

  • Global market opportunity and robust business model

  • Product validated by industry experts

  • Experienced management team with industry expertise